Solid lipid nanoparticles: An effective lipid based technology for poorly water soluble drugs

International Journal of Pharmaceutical Sciences Review and Research

Volumn 5, Issue 2, 2010, Pages 78-90

  Kamboj, Sunil ^a   Bala, Suman ^a   Nair, Anroop B ^a  

^a MAHARISHI MARKANDESHWAR DEEMED TO BE UNIVERSITY   (India)

Author keywords

Bioavailability enhancement; Colloidal carriers; Homogenization; Solid lipid nanoparticles

Indexed keywords

CAMPTOTHECIN; DIETHYLTOLUAMIDE; DRUG CARRIER; FREUND ADJUVANT; INSECT REPELLENT; LIPOSOME; PACLITAXEL; PERFUME; PIRIBEDIL; SOLID LIPID NANOPARTICLE;

COLLOID; COMPARATIVE EFFECTIVENESS; CONTROLLED RELEASE FORMULATION; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG UPTAKE; EVAPORATION; FIRST PASS EFFECT; INTESTINE MUCOSA PERMEABILITY; LIPOPHILICITY; LIPOSOMAL DELIVERY; MEAN RESIDENCE TIME; MICROEMULSION; NANOENCAPSULATION; NANOFABRICATION; NANOPHARMACEUTICS; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; REVIEW; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; STOMACH EMPTYING; SUPERCRITICAL FLUID EXTRACTION; ULTRASOUND; ZETA POTENTIAL;

EID: 79952010666     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Muller RH and Souto EB. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm, 317, 2006, 82-89.
2. Fichera M, Keck C and Muller RH. Drug nanocrystals for the delivery of poorly soluble drugs. Particles. Orlando, 2004, 272.
3. Sridevi S, Chauhan AS, Chalasani KB, Jain AK and Diwan PV. Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propylbeta-cyclodextrin. Pharmazie, 58, 2003, 807-810.
4. Fernandes CM, Ramos P, Falcao AC and Veiga FJ. Hydrophilic and hydrophobic cyclodextrins in a new sustained release oral formulation of nicardipine: in vitro evaluation and bioavailability studies in rabbits. J Controlled Release, 88, 2003, 127-134.
5. Vonderscher J and Meinzer A. Rationale for the development of sandimmune neoral. Transplant. Proc, 26, 1994, 2925-2927.
6. Meinzer A, Muller E and Vonderscher J. Perorale mikroemulsionsformulierung-mandimmun optoral/neoral. In: Muller RH and Hildebrandt GE, eds. Pharmazeutische technologue: Moderne arzneiformen. Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1998, 169-177.
7. Shidhaye SS, Vaidya R, Sutar S, Patwardhan A and Kadam VJ. Solid lipid nanoparticles and nano structured lipid carriers-innovative generations of solid lipid carriers. Current Drug Delivery, 5, 2008, 324-331.
8. Muller RH, Mader K and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm, 50, 2000, 161-177.
9. Diederichs JE and Mullar RH. Liposomen in kosmetika and arzneimitteln. Pharm Ind, 56, 1994, 267-275.
10. Esposito E. Innovative Nanotechnology based system for dermal application. http://www.pharmainfo.net.2005.
11. Fahr A, Kissel T. Pharmazeutische technologiemoderne arzneiformen. In: Muller RH and Hildebrand GE, ed. Mikropartikel und implantate arzneiformen zur parenteralen applikation. Auflage. Stuttgart. Wissenschaftliche Verlagsgesellschaft mbH, 1998, 243-258.
12. Smith A and Hunneyball IM. Evaluation of poly(lactic acid) as a biodegradable drug delivery system for parenteral administration. Int J Pharm, 30, 1986, 215-220.
13. Radtke M, Souto EB, Muller RH. NLC-the novel generation of solid lipid carriers. Pharm Tech Europe, 17, 2005, 45-50.
14. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, selfemulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci, 11 (Supplement 2), 2000, S93-S98.
15. Wasan KM. Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. Drug Dev Ind Pharm, 27(4), 2001, 267-276.
16. Dunn RL. The atrigel drug delivery system. In: Rathbone MJ, Hadgraft J and Roberts M, eds. Modified-Release Drug Delivery Technology. New York. NY: Marcel Dekker. Inc, 2002, 647-655.
17. Castelli F, Puglia C, SArpietro MG, Rizza L and Bonina F. Characterization of indomethacin-loaded nanoparticles by differential scanning calorimetry. Int J Pharm, 304, 2005, 231-238.
18. Radtke M and Muller RH. Nanostructured lipid drug carriers. New Drugs, 2, 2001, 48-52.
19. Jores K, Mehnert W, Bunjes H, Drechsler M and Mader K. Solid lipid nanoparticles (SLN) to nanospoons. Visions and reality of colloidal lipid dispersions. International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Nuremberg, Germany, March, 2008, 15-18.
20. Saupe A, Gordon KV and Rades T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and raman spectroscopy. Int J Pharm, 314(1), 2006, 56-62.
21. Venkateshwarlu V and Manjunath K. Preparation and in vitro release kinetics of clozapine solid lipid nanoparticles. J Controlled Release, 95, 2004, 627-638.
22. Kayser O, Lemke A and Hernandez-Trejo N. The Impact of nanobiotechnology on the development of new drug delivery sytems. Current Pharmaceutical Biotechnology, 6, 2005, 3-5.
23. Lobenberg R and Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system; new scientific approaches to international regulatory standards. Eur J Pharm Biopharm, 50, 2000, 3-12.
24. Dahan A and Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Controlled Release, 129, 2008, 1-10.
25. Fleisher D, Li C, Zhou Y, Pao LH and Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications, Clin. Pharmacokinet, 36(3), 1999, 233-254.
26. Tso P. Gastrointestinal digestion and absorption of lipid. Adv Lipid Res, 21, 1985, 143-186.
27. Kossena G, Charman W, Wilson C, O'Mahony B, Lindsay B, Hempenstall J, Davison C, Crowley P and Porter C. Low dose lipid formulations: effects on gastric emptying and biliary secretion. Pharm Res, 24(11), 2007, 2084-2096.
28. Citters GWV and Lin HC. The ideal brake: a fifteenyear progress report, Curr Gastroenterol Rep, 1(5), 1999, 404-409.
29. Constantinides PP and Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of p-glycoprotein (p-gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci, 96(2), 2007, 235-248.
30. Dintaman JM and Silverman JA. Inhibition of pglycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res, 16(10), 1999, 1550-1556.
31. Nerurkar MM, Burton PS and Borchardt RT. The use of surfactants to enhance the permeability of peptides through caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res, 13(4), 1996, 528-534.
32. Chakraborty S, Shukla D, Mishra B and Singh S. Lipid-an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm, 73, 2009, 1-15.
33. Dahan A and Hoffman A. Enhanced gastrointestinal absorption of lipophilic drugs. In: Touitou E and Barry BW, ed. Enhancement in drug delivery. CRC press, 2006, 111-127.
34. Charman WN, Porter CJH, Mithani S and Dressman JB. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci, 86(3), 1997, 269-282.
35. Friedman HI and Nylund B. Intestinal fat digestion, absorption, and transport. a review. Am J Clin Nutr, 33(5), 1980, 1108-1139.
36. Charman WN and Stella VJ. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm, 34, 1986, 175-178.
37. Thomson ABR, Keelan M, Garg ML and Clandinin MT. Intestinal aspects of lipid absorption: in review. Can J Physiol Pharmacol, 67, 1989, 179-191.
38. Leak LV. The structure of lymphatic capillaries in lymph formation. Fed Proc, 35, 1976, 1863-1871.
39. Shehe DM, Green JB and Green MH. Influence of dietary fat saturation on lipid absorption in the rat. Atherosclerosis, 37, 1989, 301-310.
40. Feldman EB, Russel BS, Chen R, Johnson J, Forte T and Clark SB. Dietary saturated fatty acid content affects lymph lipoproteins: studies in the rat. J Lipid Res, 2, 1983, 967-976.
41. Green PH and Glickman RM. Intestinal lipoprotein metabolism. J Lipid Res, 22, 1981, 1153-1173.
42. Cheema M, Palin KJ and Davis SS. Lipid vehicles for intestinal lymphatic drug absorption. J Pharm Pharmacol, 39, 1987, 55-56.
43. Ockner RK, Pittman JP and Yager JL. Differences in the intestinal absorption of saturated and unsaturated long chain fatty acids. Gastroenterology, 62, 1972, 981-992.
44. Bergstedt SE, Hayashi H, Kritchevsky D and Tso P. A comparison of absorption of glycerol tristearate and glycerol trioleate by rat small intestine. Am J Physiol, 259, 1990, G386-G393.
45. Zuther JE. Anatomy, in: lymphedema management: the comprehensive guide for ractitioners. Thieme Medical Publishers Inc. New York, 2005, 1-28.
46. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci, 29, 2006, 278-287.
47. Pouton CW and Porter CJH. Formulation of lipidbased delivery systems for oral administration: materials methods and strategies. Adv Drug Del Rev, 60, 2008, 625-637.
48. Cense HA, Eijck CHV and Tilanus HW. New insights in the lymphatic spread of oesophageal cancer and its implications for the extent of surgical resection. Best Pract Res Clin Gastroenterol, 20, 2006, 893-906.
49. Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M and Patel HR. The metastatic cascade in prostate cancer. Surg Oncol, 15, 2006, 117-128.
50. Muranishi S. Lymphatic delivery of drugs and its application to cancer chemotherapy. Yakugaku Zasshi, 100, 1980, 687-698.
51. Aburbeh AG, Poupaert JH, Claesen M, Dumont P and Atassi G. 1, 3-dipalmitoylglycerol ester of chlorambucil as a lymphotropic, orally administrable antineoplastic agent. J Med Chem, 26, 1983, 1200-1203.
52. Pantaleo G, Graziosi C, Demarest JF, Cohen OJ, Vaccarezza M, Gantt, Muro CC and Fauci AS. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol Rev, 140, 1994, 105-130.
53. Pantaleo G, Graziosi C and Fauci AS. The role of lymphoid organs in the immunopathogenesis of HIV infection. Aids, 7, 1993, S19-S23.
54. Lalanne M, Paci A, Andrieux K, Bosquet ND, Clayette P, Deroussent A, Vassal MRG, Couvreur P and Desmaele D. Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV. Bioorg Med Chem Lett, 17, 2007, 2237-2240.
55. Umeda M, Marusawa H, Seno H, Katsurada A, Nabeshima M, Egawa H, Uemoto S, Inomata Y, Tanaka K and Chiba T. Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers. J Hepatol, 42, 2005, 806-812.
56. Messling VV, Svitek N and Cattaneo R. Receptor (SLAM [CD150]) recognition and the V protein sustain swift lymphocyte-based invasion of mucosal tissue and lymphatic organs by a morbillivirus. J Virol, 80, 2006, 6084-6092.
57. Lan NT, Yamaguchi R, Inomata A, Furuya Y, Uchida K, Sugano S, Sugano S and Tateyama S. Comparative analyses of canine distemper viral isolates from clinical cases of canine distemper in vaccinated dogs. Vet Microbiol, 115, 2006, 32-42.
58. Spiegel M, Schneider K, Weber F, Weidmann M and Hufert FT. Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells. J Gen Virol, 87, 2006, 1953-1960.
59. Kessel A and Toubi E. Chronic HCV-related autoimmunity: a consequence of viral persistence and lymphotropism. Curr Med Chem, 14, 2007, 547-554.
60. Yokoyama M. Block copolymers as drug carriers. Crit Rev Ther Drug Carrier Syst, 9, 1992, 213-248.
61. Hwang KJ and Mauk MR. Fate of lipid vesicles in vivo: a gamma-ray perturbed angular correlation study. Proc Natl Acad Sci USA-Biophys, 74, 1977, 4991-4995.
62. Mehnert W and Mader K. Solid lipid nanoparticles production, characterization and applications. Advanced Drug Delivery Reviews, 47, 2001, 165-196.
63. Lippacher A, Muller RH and Mader K. Investigation on the viscoelastic properties of lipid based colloidal drug carriers. Int J Pharm, 196, 2000, 227-230.
64. Muller RH, Mehnert W, Lucks JS, Schwarz C, Muhlen A, Weyhers H, Freitas C and Ruhl D. Solid lipid nanoparticles (SLN)-An alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm, 41, 1995, 62-69.
65. Muhlen A and Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie, 53, 1998, 552-555.
66. Muhlen A, Schwarz C and Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm, 45, 1998, 149-155.
67. Lander R, Manger W, Scouloudis M, Davis AKC and Lee A. Gaulin homogenization: a mechanistic study. Biotech-nol. Prog, 16, 2000, 80-85.
68. Jahnke S. The theory of high pressure homogenization. In: Muller RH, Benita S and Bohm B, eds. Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs. Medpharm Scientific Publishers. Stuttgart, 1998, 177-200.
69. Siekmann B and Westesen K. Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol. preparation and particle size determination. Pharm Pharmacol Lett, 3, 1994, 194-197.
70. Mukhrjee S, Ray S and Thakur S. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian journal of pharmaceutical sciences, 71(4), 2010, 349-358.
71. Eldem T, Speiser P and Hincal A. Optimization of spray-dried and congealed lipid microparticles and xharacterization of their surface morphology by scanning electron microscopy. Pharm Res, 8, 1991, 47-54.
72. Speiser P. lipidnanopellets als Tragersystem fur Arzneimittel zur peroralem Anwendung. European patent, EP 0167825, 1990.
73. Sjostrom B and Bergenstahl B. prepration of submicron drug particles in lecithin-stabilized o/w emulsions: I: model studies of the precipitation of cholesteryl acetate. Int J Pharm, 88, 1992, 53-62.
74. Siekmann B and Westesen K. Investigations of solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur J Pharm Biopharm, 43, 1996, 104-109.
75. Chen YJ, Jin RX, Zhou YQ, Zeng J, Zhang H and Feng QR. Preparation of solid lipid nanoparticle loaded with Xionggui powder-supercritical carbon dioxide fluid extraction and their evaluation in vitro release. Zhongguo Zhong Yao Za Zhi, 31, 2006, 376-379.
76. Kaiser CS, Rompp H and Schmidt PC. Pharmaceutical applications of supercritical carbon dioxide. Pharmazie, 56, 2001, 907-926.
77. Gosselin PM, Thibert R, Preda M and Macmullen JN. Polymeric properties of micronized carbamazepine produced by RESS. Int J Pharm, 252, 2003, 225-233.
78. Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. United States Patent, USS 188837, 1993.
79. Gasco MR. Solid lipid nanospheres from warm micronanoparticles emulsions. Pharm Tech Eur, 9, 1997, 52-58.
80. Boltri L, Canal T, Esposito PA and Carli F. Lipid nanoparticles: evaluation of some critical formulation parameters. Proc Intern Symp. Control Release Bioact Mater, 20, 1993, 346-347.
81. Muchow M, Maincent P and Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Development and Industrial Pharmacy, 34, 2008, 1394-1405.
82. Cavalli R Marengo E, Rodriguez L and Gasco MR. Effect of some experimental factors on the production process of solid lipid nanoparticles. Eur J Pharm Biopharm, 43, 1996, 110-115.
83. Gasco MR, Morel S and Carpigno R. Optimization of the incorporation of desoxycortisone acetate in lipospheres. Eur J Pharm Biopharm, 38, 1992, 7-10.
84. Freitas C and Muller RH. Spray-drying of solid lipid nanoparticles (SLN TM). Eur J Pharm Biopharm, 46, 1998, 145-151.
85. Sato K. Crystallization of fats and fatty acids. in: Garti N ans Sato K, ed. Crystallization and Polymorphism of Fatsand Fatty Acids. Marcel Dekker Inc. New York, Basel, 1998, 227-266.
86. Muller RH. Zetapotential und partikelladung in der laborpraxis-einfuhrung in die theorie. praktische meßdurch-fuhrung. dateninterpretation, wissenschaftliche verlags-gesellschaft. Stuttgart, 1996.
87. Kobayashi M. Vibrational spectroscopic aspects of polymorphism and phase transition of fats and fatty acids. In: Garti N and Sato K, eds. Crystallization and Polymorphism of Fats and Fatty Acids. Marcel Dekker Inc. New York. Basel, 1988, 139-188.
88. Jenning V. Feste lipid nanopartikelals tragersystem furdie dermale applikation von retinol. Ph.D. thesis. Free University of Berlin, 1999.
89. Zimmermann E, Liedtke S, Muller RH and Mader K. HNMR as a method to characterize colloidal carrier systems. Proc Int Symp. Control Release Bioact Mater, 26, 1999, 591-592.
90. Wissing SA, Muller RH, Manthei L and Mayer C. Structural characterization of Q10-loaded solid lipid nanoparticles by NMR spectroscopy. Pharm Res, 21, 2004, 400-405.
91. Liedtke S, Zimmermann E, Muller RH and Mader K. Physical characterisation of solid lipid nanoparticles (SLNs). Proc Int Symp. Control. Release Bioact Mater, 26, 1999, 599-600.
92. Pinto JF and Muller RH. Pellets as carriers of solid lipid nanoparticles (SLN) for oral administration of drugs. Pharmazie, 54, 1999, 506-509.
93. Yang S, Zhu J, Lu Y, Liang B and Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Re, 16, 1999, 751-757.
94. Wissing SA, Kayser O and Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 56, 2004, 1257-1272.
95. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW and Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Controlled Release, 59(3), 1999, 299-307.
96. Goppert T and Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. Journal of Drug Targeting, 13(3), 2005, 179-87.
97. Cavalli R, Caputo O and Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci, 10, 2000, 305-309.
98. Bocca C, Caputo O, Cavalli R, Gabriel L, Miglietta A and Gasco MR. Phagocytic uptake of fluorescent stealth and non-stealrh solid lipoid nanoparticles. Int J Pharm, 175, 1998, 185-193.
99. Cavalli R, Bocca C, Miglietta A, Caputo O and Gasco MR. Albumin adsorption on stealth and non-stealth solid lipid nanoparticles. STP Pharma Sci, 9, 1999, 183-189.
100. Tabatt K. Ph.D thesis-http://www.diss.fuberlin.de/2003/6/in-dexe.html pharmaceuticalbiotechnological applications of solid lipid nanoparticles (SLN): vaccine adjuvants and gene transfer vehicles, 2003.
101. Tabatt K, Kneuer C, Sameti M, Olbrich C, Muller RH, Lehr C and Bakowsky U. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J Controlled Release, 97, 2004, 321-332.
102. Muller RH, Wissing S and Mader K. Sunscreens containing uv radiation reflecting or absorbing agents, protecting against harmful uv radiation and reinforcing the natural skin barrier. PCT Int. Appl, WO 01/03652, 2001.
103. Muller RH, Radtke M and Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drug. Int J Pharm, 242, 2002, 121-128.
104. Wissing SA, Mader K and Muller RH. Solid lipid nanoparticles (SLN) as a novel carrier system offering prolonged release of the perfume allure (Chanel). Proc Int Symp. Control Release Bioact Mater, 27, 2000, 311-312.
105. Muller RH, Radtke M and Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 54, 2002, S131-S15.